{"content":"<li class=\"n-box-item date-title\" data-end=\"1514350799\" data-start=\"1514264400\" data-txt=\"Monday, December 23, 2019\">Tuesday, December 26, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3320100\" data-ts=\"1514324278\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HTGM\" target=\"_blank\">HTGM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320100-htg-molecular-diagnosticsplus-19_6-on-merck-collab-expansion\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HTG Molecular Diagnostics +19.6% on Merck collab expansion</a></h4><ul><li>        HTG Molecular Diagnostics (NASDAQ:<a href='https://seekingalpha.com/symbol/HTGM' title='HTG Molecular Diagnostics'>HTGM</a>) <a href=\"https://seekingalpha.com/pr/17034081-htg-molecular-diagnostics-expands-collaboration-merck-kgaa-darmstadt-germany\" target=\"_blank\">announces</a> a new collaboration agreement for translational programs with Merck KGaA.</li><li>               The collab expands the previously announced master companion diagnostic agreement with Merck and includes a statement of work with EMD Serono, the biopharma business of Merck.&nbsp;</li><li>               Under the first program, HTG plans to develop and create a custom profiling assay to aid research for six indications within Merck&rsquo;s pipeline.&nbsp;</li><li>               HTG shares are&nbsp;<font color='green'>up 19.6%</font>.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3320100\" data-linked=\"HTG Molecular Diagnostics +19.6% on Merck collab expansion\" data-tweet=\"$HTGM - HTG Molecular Diagnostics +19.6% on Merck collab expansion https://seekingalpha.com/news/3320100-htg-molecular-diagnosticsplus-19_6-on-merck-collab-expansion?source=tweet\" data-url=\"https://seekingalpha.com/news/3320100-htg-molecular-diagnosticsplus-19_6-on-merck-collab-expansion\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320092\" data-ts=\"1514323375\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WATT\" target=\"_blank\">WATT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320092-energousplus-63-on-fcc-certification\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energous +63% on FCC certification</a></h4><ul><li>        Energous (NASDAQ:<a href='https://seekingalpha.com/symbol/WATT' title='Energous Corp.'>WATT</a>) <a href=\"https://seekingalpha.com/pr/17034083-energous-receives-industry-first-fcc-certification-air-power-distance-wireless-charging\" target=\"_blank\">announces</a> the FCC certification of its first-gen WattUp Mid Field transmitter.</li><li>               The certification was the FCC&rsquo;s first Part 18 approval for power-at-a-distance wireless charging.&nbsp;&nbsp;</li><li>               Energous shares are&nbsp;<font color='green'>up 62.7%.</font>&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3320092\" data-linked=\"Energous +63% on FCC certification\" data-tweet=\"$WATT - Energous +63% on FCC certification https://seekingalpha.com/news/3320092-energousplus-63-on-fcc-certification?source=tweet\" data-url=\"https://seekingalpha.com/news/3320092-energousplus-63-on-fcc-certification\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>257&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320084\" data-ts=\"1514319988\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320084-top-tech-etfs-in-2017\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Top tech ETFs in 2017</a></h4><ul><li>        Nearing the end of 2017, here are the top tech ETFs according to YTD performance.</li><li>               ARK Innovation ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/ARKK' title='ARK Innovation ETF'>ARKK</a>):&nbsp;<font color='green'>+88.3%</font>.&nbsp;&nbsp;</li><li>               ARK Web x.0 ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/ARKW' title='ARK Web x.0 ETF'>ARKW</a>):&nbsp;<font color='green'>+87.9%</font>.&nbsp;</li><li>               Guggenheim China Technology ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/CQQQ' title='Guggenheim China Technology ETF'>CQQQ</a>):&nbsp;<font color='green'>+74.1%</font>.&nbsp;</li><li>                  Emerging Markets Internet and Ecommerce ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/EMQQ' title='Emerging Markets Internet & Ecommerce ETF'>EMQQ</a>):&nbsp;<font color='green'>+68.2%</font>.    </li><li>               PureFunds Video Game Tech ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/GAMR' title='PureFunds Video Game Tech ETF'>GAMR</a>):&nbsp;<font color='green'>+59%</font>.&nbsp;</li><li>               Global X Social Media Index ETF (NASDAQ:<a href='https://seekingalpha.com/symbol/SOCL' title='Global X Social Media Index ETF'>SOCL</a>):&nbsp;<font color='green'>+57%</font>.&nbsp;</li><li>               Global X FinTech Thematic ETF (NASDAQ:<a href='https://seekingalpha.com/symbol/FINX' title='Global X FinTech Thematic ETF'>FINX</a>):&nbsp;<font color='green'>+49.9%</font>.&nbsp;</li><li>               Global X NASDAQ China Technology ETF (NASDAQ:<a href='https://seekingalpha.com/symbol/QQQC' title='Global X China Technology ETF'>QQQC</a>):&nbsp;<font color='green'>+47.9%</font>.&nbsp;</li><li>               Robo Global Robotics and Automation Index ETF (NASDAQ:<a href='https://seekingalpha.com/symbol/ROBO' title='ROBO Global Robotics and Automation Index ETF'>ROBO</a>):&nbsp;<font color='green'>+44.3%</font>.&nbsp;</li><li>                  iShares North American Tech Software ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/IGV' title='iShares North American Tech-Software ETF'>IGV</a>):&nbsp;<font color='green'>+42.5%</font>. &nbsp;<br />   &nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3320084\" data-linked=\"Top tech ETFs in 2017\" data-tweet=\"$ARKK $ARKW $CQQQ - Top tech ETFs in 2017 https://seekingalpha.com/news/3320084-top-tech-etfs-in-2017?source=tweet\" data-url=\"https://seekingalpha.com/news/3320084-top-tech-etfs-in-2017\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320078\" data-ts=\"1514315619\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEUM\" target=\"_blank\">TEUM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320078-parateum-adds-cryptocurrency-support-sharesplus-61\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Parateum adds cryptocurrency support, shares +61%</a></h4><ul><li>        Parateum (NYSEMKT:<a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a>) <a href=\"https://seekingalpha.com/pr/17034064-pareteum-adds-blockchain-settlement-cryptocurrency-global-cloud-platform\" target=\"_blank\">adds support</a> for blockchain tech in its billing and settlement services.</li><li>           Global Mobility Cloud customers can accept and process Bitcoin, Ethereum, Litecoin, Airtokens and other forms of cryptocurrency.&nbsp; </li><li> Parateum shares are&nbsp;<font color='green'>up 61%</font>.&nbsp;<br />&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3320078\" data-linked=\"Parateum adds cryptocurrency support, shares +61%\" data-tweet=\"$TEUM - Parateum adds cryptocurrency support, shares +61% https://seekingalpha.com/news/3320078-parateum-adds-cryptocurrency-support-sharesplus-61?source=tweet\" data-url=\"https://seekingalpha.com/news/3320078-parateum-adds-cryptocurrency-support-sharesplus-61\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320077\" data-ts=\"1514315342\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNK\" target=\"_blank\">MNK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320077-sucampo-may-get-higher-bid-nomura\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sucampo may get higher bid - Nomura</a></h4><ul><li>The company's Phase 2/3&nbsp;pipeline asset VTS-270 for Niemann-Pick Disease Type C1 alone could be worth $29 per share, says analyst Chris Marai. This vs.&nbsp;Mallinckrodt&rsquo;s (<a href='https://seekingalpha.com/symbol/MNK' title='Mallinckrodt PLC'>MNK</a> <font color='green'>+0.9%</font>) $18 per share offer.</li><li>The Street, says Marai, has&nbsp;fundamentally mis-modeled Sucampo's (NASDAQ:<a href='https://seekingalpha.com/symbol/SCMP' title='Sucampo Pharmaceuticals, Inc.'>SCMP</a>) near-term Phase 3 readout for the drug.</li><li>Marai has a $43 price target on SCMP, adding in $11 per share for Amitiza and $3 for CPP-1x/Sulindac combination.</li><li>Source: Bloomberg</li><li>SCMP is<font color='green'> up 5.9%</font>&nbsp;to $18.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3320008-mallinckrodt-seals-deal-sucampo-pharma\" target=\"_blank\">Mallinckrodt seals deal for Sucampo Pharma</a> (Dec. 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3320077\" data-linked=\"Sucampo may get higher bid - Nomura\" data-tweet=\"$MNK $MNK $SCMP - Sucampo may get higher bid - Nomura https://seekingalpha.com/news/3320077-sucampo-may-get-higher-bid-nomura?source=tweet\" data-url=\"https://seekingalpha.com/news/3320077-sucampo-may-get-higher-bid-nomura\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320076\" data-ts=\"1514314901\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320076-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/METC' title='Ramaco'>METC</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/MCF' title='Contango Oil & Gas Company'>MCF</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/KLDX' title='Klondex Mines Ltd.'>KLDX</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/MTL' title='Mechel OAO'>MTL</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/BTE' title='Baytex Energy Corp.'>BTE</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/WMLP-OLD' title='Westmoreland Resource Partners, LP'>WMLP-OLD</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/USAU' title='U.S. Gold Corp.'>USAU</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/SYNL' title='Synalloy Corporation'>SYNL</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3320076\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$METC $MCF $KLDX - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3320076-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3320076-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320072\" data-ts=\"1514311517\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320072-cnbc-amazon-planning-ad-push-in-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CNBC: Amazon planning ad push in 2018</a></h4><ul><li>        CNBC <a href=\"https://www.cnbc.com/2017/12/26/amazon-digital-advertising-push-in-2018.html\" target=\"_blank\">sources</a> say Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) is experimenting with ad products both on and off its platform for a 2018 push. &nbsp;</li><li>        Off-platform products could involve third-party mobile ad partnerships to sell TV and mobile ads.</li><li>               Platform ad experiments target e-commerce searches and video products.&nbsp;</li><li>               Why would advertisers choose Amazon over ad market leaders Google (NASDAQ:<a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet, Inc. Cl A'>GOOGL</a>) and Facebook (NASDAQ:<a href='https://seekingalpha.com/symbol/FB' title='Facebook'>FB</a>)? Sources say the tech giant has offered to share more user data if the price is right. &nbsp;&nbsp;&nbsp;</li><li>               Amazon shares are&nbsp;<font color='green'>up 0.8%</font>.&nbsp;</li><li>               Facebook shares are&nbsp;<font color='red'>down 0.3%</font>.&nbsp;</li><li>               Google shares are&nbsp;<font color='red'>down 0.3%</font>.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3320043-echo-dot-tops-amazons-holiday-sales-season\" target=\"_blank\">Echo Dot tops Amazon's holiday sales season</a> (Dec. 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3320072\" data-linked=\"CNBC: Amazon planning ad push in 2018\" data-tweet=\"$AMZN $AMZN $GOOGL - CNBC: Amazon planning ad push in 2018 https://seekingalpha.com/news/3320072-cnbc-amazon-planning-ad-push-in-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3320072-cnbc-amazon-planning-ad-push-in-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320066\" data-ts=\"1514310221\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YNDX\" target=\"_blank\">YNDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320066-yandex-buys-food-delivery-startup-to-expand-ubereats\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yandex buys food-delivery startup to expand UberEats</a></h4><ul><li>        Bloomberg <a href=\"https://www.bloomberg.com/news/articles/2017-12-25/yandex-to-expand-ubereats-in-russia-with-local-acquisition\" target=\"_blank\">reports</a> that Yandex (NASDAQ:<a href='https://seekingalpha.com/symbol/YNDX' title='Yandex N.V.'>YNDX</a>) purchased food-delivery startup Foodfox to expand the planned Uber (<a href='https://seekingalpha.com/symbol/UBER' title='Uber'>UBER</a>) merger in Russia.</li><li>                  Terms of the acquisition weren&rsquo;t disclosed but rumors put the price at under $10M.    </li><li>               Foodfox founders Maxim Firsov and Sergey Polissar will head UberEats after the merger completes in January.&nbsp;</li><li>               Foodfox works with more than 2K restaurants in Moscow compared to UberEats&rsquo; &ldquo;several hundred&rdquo; places. Delivery Club leads the regional market with 6.5K restaurants. &nbsp;&nbsp;</li><li>Yandex shares are&nbsp;<font color='green'>up 1.3%</font>.&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3314280-yandex-plus-3_8-percent-approval-merge-uber-russia\" target=\"_blank\">Yandex +3.8% on approval to merge with Uber in Russia</a> (Nov. 24)</li></ul><div class=\"tiny-share-widget\" data-id=\"3320066\" data-linked=\"Yandex buys food-delivery startup to expand UberEats\" data-tweet=\"$YNDX $YNDX $UBER - Yandex buys food-delivery startup to expand UberEats https://seekingalpha.com/news/3320066-yandex-buys-food-delivery-startup-to-expand-ubereats?source=tweet\" data-url=\"https://seekingalpha.com/news/3320066-yandex-buys-food-delivery-startup-to-expand-ubereats\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:43 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320063\" data-ts=\"1514308347\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTL\" target=\"_blank\">MTL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320063-mechelplus-10-on-deal-to-expand-mining-machinery-fleet\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mechel +10% on deal to expand mining machinery fleet</a></h4><ul>     <li>Mechel (<a href='https://seekingalpha.com/symbol/MTL' title='Mechel OAO'>MTL</a> <font color='green'>+10.7%</font>) surges following news it is <a href=\"https://globenewswire.com/news-release/2017/12/26/1274569/0/en/Mechel-Expands-Mining-Machinery-Fleet-at-Southern-Yakutia-Industrial-Facilities.html\" target=\"_blank\">expanding its mining machinery fleet</a> in southern Yakutia, leasing 18 BelAZ mining trucks as part of an agreement with Russia's State Transport Leasing for 2.8B rubles.</li>     <li>Mechel Mining Management head Pavel Shtark says the deal will enable the company to increase the volume of coal being prepared for mining and, as a result, increase production in  2018.</li>     <li>On Friday, MTL said it secured a <a href=\"https://globenewswire.com/news-release/2017/12/21/1269076/0/en/Mechel-Reports-Izhstal-Getting-Export-Loan-From-Eximbank-of-Russia.html\" target=\"_blank\">loan agreement</a> opening a credit line totaling 3.35B rubles for two and a half years to finance high technology product manufacturing for export contracts.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3320063\" data-linked=\"Mechel +10% on deal to expand mining machinery fleet\" data-tweet=\"$MTL - Mechel +10% on deal to expand mining machinery fleet https://seekingalpha.com/news/3320063-mechelplus-10-on-deal-to-expand-mining-machinery-fleet?source=tweet\" data-url=\"https://seekingalpha.com/news/3320063-mechelplus-10-on-deal-to-expand-mining-machinery-fleet\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:12 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320061\" data-ts=\"1514308078\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDC\" target=\"_blank\">WDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320061-benchmark-defends-western-digital-on-memory-market-concerns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Benchmark defends Western Digital on memory market concerns</a></h4><ul><li>           The Benchmark Company <a href=\"http://www.briefing.com/DisplayArticle/ArticlePopup.aspx?ArticleId=IN20171226090631WDC\" target=\"_blank\">defends</a> Western Digital (NYSE:<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>) against investor concerns that memory prices will lower as capacity builds. </li><li> Benchmark expects 35% to 45% Y/Y growth in NAND bit demand and says that should mitigate the pricing impact next year. </li><li>           Benchmark calls Western Digital a compelling opportunity at its current share price and assigns a $130 target price based on a forward multiple of 10.4 on the FY19 estimate. </li><li> Western Digital shares are&nbsp;<font color='red'>down 1.5%</font>. &nbsp;&nbsp;&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3320061\" data-linked=\"Benchmark defends Western Digital on memory market concerns\" data-tweet=\"$WDC - Benchmark defends Western Digital on memory market concerns https://seekingalpha.com/news/3320061-benchmark-defends-western-digital-on-memory-market-concerns?source=tweet\" data-url=\"https://seekingalpha.com/news/3320061-benchmark-defends-western-digital-on-memory-market-concerns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320060\" data-ts=\"1514307755\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320060-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ADOM' title='ADOMANI, Inc.'>ADOM</a> <font color='green'>+45%</font>. <a href='https://seekingalpha.com/symbol/FTFT' title='Future Fintech Group Inc'>FTFT</a> <font color='green'>+45%</font>. <a href='https://seekingalpha.com/symbol/FUV' title='Arcimoto, Inc.'>FUV</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/WPRT' title='Westport Fuel Systems, Inc.'>WPRT</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/FOSL' title='Fossil, Inc.'>FOSL</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> LTEA <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/LCUT' title='Lifetime Brands, Inc.'>LCUT</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/SPAR' title='Spartan Motors, Inc.'>SPAR</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/ANFI' title='Amira Nature Foods'>ANFI</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/JAKK' title='JAKKS Pacific, Inc.'>JAKK</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3320060\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$ADOM $FTFT $FUV - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3320060-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3320060-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320058\" data-ts=\"1514306644\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QGEN\" target=\"_blank\">QGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320058-qiagen-will-take-charges-due-to-u-s-tax-law\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Qiagen will take charges due to U.S. tax law</a></h4><ul><li>        Qiagen (NASDAQ:<a href='https://seekingalpha.com/symbol/QGEN' title='Qiagen N.V.'>QGEN</a>) <a href=\"https://seekingalpha.com/pr/17033766-qiagen-take-impairment-deferred-tax-assets-informs-expected-impacts-new-u-s-tax-law-changes\" target=\"_blank\">announces</a> plans to take a Q4 after-tax charge on net income of $110M to $120M ($0.47 to $0.52 per share).</li><li>               Qiagen attributes the charge to the new U.S. tax legislation.&nbsp;</li><li>                  The company will take an additional $7M ($0.03 per share) after-tax charge in 2018.    </li><li>               Qiagen shares are&nbsp;<font color='red'>down 1.5%</font>. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3318764-oxford-immunotec-qiagen-settle-patent-litigation\" target=\"_blank\">Oxford Immunotec, Qiagen settle patent litigation</a> (Dec. 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3320058\" data-linked=\"Qiagen will take charges due to U.S. tax law\" data-tweet=\"$QGEN - Qiagen will take charges due to U.S. tax law https://seekingalpha.com/news/3320058-qiagen-will-take-charges-due-to-u-s-tax-law?source=tweet\" data-url=\"https://seekingalpha.com/news/3320058-qiagen-will-take-charges-due-to-u-s-tax-law\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320057\" data-ts=\"1514306065\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLWS\" target=\"_blank\">FLWS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320057-northcoast-downgrades-1minus-800-flowers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Northcoast downgrades 1-800-Flowers</a></h4><ul><li>        Northcoast<a href=\"https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=1&amp;cad=rja&amp;uact=8&amp;ved=0ahUKEwi86ZzLjKjYAhWGw4MKHTqZCOIQFgjPATAA&amp;url=https%3A%2F%2Fwww.streetinsider.com%2FAnalyst%2BComments%2FNorthcoast%2BResearch%2BDowngrades%2B1-800-FLOWERS.COM%2B%28FLWS%29%2Bto%2BNeutral%2F13629973.html&amp;usg=AOvVaw0tLQGot2BcLfIdZUv4YIUF\" target=\"_blank\"> downgrades</a> 1-800-Flowers (NASDAQ:<a href='https://seekingalpha.com/symbol/FLWS' title='1-800 FLOWERS.COM, Inc.'>FLWS</a>) from Buy to Neutral.</li><li>               Analyst Kara Szafraniec cites the equity spot nearing the previous price target of $12.&nbsp;</li><li>               1-800-Flowers shares are&nbsp;<font color='red'>down 2.4%</font>.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3320057\" data-linked=\"Northcoast downgrades 1-800-Flowers\" data-tweet=\"$FLWS - Northcoast downgrades 1-800-Flowers https://seekingalpha.com/news/3320057-northcoast-downgrades-1minus-800-flowers?source=tweet\" data-url=\"https://seekingalpha.com/news/3320057-northcoast-downgrades-1minus-800-flowers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:34 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320055\" data-ts=\"1514305493\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INTC\" target=\"_blank\">INTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320055-mizuho-says-intel-positioned-well-for-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mizuho says Intel positioned well for 2018</a></h4><ul><li>        Mizuho reinitiates Intel (NASDAQ:<a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a>) with a Buy rating and $47 price target. The firm plans to review the price target closer to earnings.&nbsp;</li><li>           Firm says Intel had a solid run this year and stands well positioned for 2018. </li><li> Mizuho thinks March quarter consensus estimates are modestly high but sees the company becoming a key beneficiary of the lowered U.S. corporate tax. &nbsp;&nbsp; </li><li> Intel shares are&nbsp;<font color='red'>down 1%</font>.&nbsp;&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3320037-intel-loses-semi-lead-first-time-25-years\" target=\"_blank\">Intel loses semi lead for first time in 25 years</a> (Dec. 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3320055\" data-linked=\"Mizuho says Intel positioned well for 2018\" data-tweet=\"$INTC - Mizuho says Intel positioned well for 2018 https://seekingalpha.com/news/3320055-mizuho-says-intel-positioned-well-for-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3320055-mizuho-says-intel-positioned-well-for-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320054\" data-ts=\"1514304335\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KNL\" target=\"_blank\">KNL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320054-raymond-james-upgrades-knoll-raises-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Raymond James upgrades Knoll, raises its price target</a></h4><ul><li>        Raymond James <a href=\"http://www.briefing.com/DisplayArticle/ArticlePopup.aspx?ArticleId=IN20171226082024KNL\" target=\"_blank\">upgrades</a> Knoll (NYSE:<a href='https://seekingalpha.com/symbol/KNL' title='Knoll, Inc.'>KNL</a>) from Outperform to Strong Buy and raises its price target by $3 to $26.</li><li>               Analyst Budd Bugatch cites US tax reform and the company&rsquo;s sales force, new products, and the recently announced Muuto acquisition.&nbsp;</li><li>               Knoll shares are&nbsp;<font color='green'>up 4.3%</font>. &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3318094-knoll-acquire-muuto\" target=\"_blank\">Knoll to acquire Muuto</a> (Dec. 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3320054\" data-linked=\"Raymond James upgrades Knoll, raises its price target\" data-tweet=\"$KNL - Raymond James upgrades Knoll, raises its price target https://seekingalpha.com/news/3320054-raymond-james-upgrades-knoll-raises-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3320054-raymond-james-upgrades-knoll-raises-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:05 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320052\" data-ts=\"1514304156\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HCLP\" target=\"_blank\">HCLP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320052-hi-crush-partners-jumps-on-new-term-loan-revolving-credit-agreements\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hi-Crush Partners jumps on new term loan, revolving credit agreements</a></h4><ul>     <li>Hi-Crush Partners (<a href='https://seekingalpha.com/symbol/HCLP' title='Hi-Crush Partners LP'>HCLP</a> <font color='green'>+3.5%</font>) is higher after saying it entered into a <a href=\"https://seekingalpha.com/pr/17033904-hi-crush-partners-lp-announces-successful-refinancing-transactions-unit-repurchase-program\" target=\"_blank\">new $200M senior secured term loan credit agreement</a> and a new five-year revolving credit agreement.</li>     <li>The new $200M term loan extends the maturity on the previous $200M term loan credit facility to December 2024 from April 2021, and the new five-year $125M revolving credit agreement replaces the previous $75M facility and extends the maturity to December 2022 from December 2019.</li>     <li>HCLP also says it repurchased more than 2M common units in Q4 worth ~$20M since announcing its unit buyback program of up to $100M in October.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3320052\" data-linked=\"Hi-Crush Partners jumps on new term loan, revolving credit agreements\" data-tweet=\"$HCLP $HCR - Hi-Crush Partners jumps on new term loan, revolving credit agreements https://seekingalpha.com/news/3320052-hi-crush-partners-jumps-on-new-term-loan-revolving-credit-agreements?source=tweet\" data-url=\"https://seekingalpha.com/news/3320052-hi-crush-partners-jumps-on-new-term-loan-revolving-credit-agreements\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320041\" data-ts=\"1514304107\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320041-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/APTO' title='Aptose Biosciences Inc.'>APTO</a> <font color='green'>+30%</font>. <a href='https://seekingalpha.com/symbol/AMPE' title='Ampio Pharmaceuticals, Inc.'>AMPE</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/INSY' title='Insys Therapeutics, Inc.'>INSY</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/CERC' title='Cerecor'>CERC</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/MGEN' title='Miragen Therapeutics, Inc.'>MGEN</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/PTLA' title='Portola Pharmaceuticals'>PTLA</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/AFMD' title='Affimed Therapeutics'>AFMD</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/HAIR' title='Restoration Robotics'>HAIR</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/NURO' title='NeuroMetrix, Inc.'>NURO</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3320041\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$APTO $AMPE $INSYQ - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3320041-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3320041-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320050\" data-ts=\"1514303733\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XPO\" target=\"_blank\">XPO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320050-citigroup-raises-xpo-logistics-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Citigroup raises its XPO Logistics price target</a></h4><ul><li>        Citigroup raises its XPO Logistics (NYSEMKT:<a href='https://seekingalpha.com/symbol/XPO' title='XPO Logistics, Inc'>XPO</a>) price target from $75 to $110 and maintains a Buy rating.</li><li>               Firm cites last week&rsquo;s news that Home Depot is considering acquiring the company to block Amazon. &nbsp;&nbsp;</li><li>               XPO shares are&nbsp;<font color='red'>down 1%</font>&nbsp;pulling back after the acquisition news bump.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3319916-xpo-logistics-plus-11-percent-reported-takeover-interest-home-depot\" target=\"_blank\">XPO Logistics +11% on reported takeover interest from Home Depot</a> (Dec. 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3320050\" data-linked=\"Citigroup raises its XPO Logistics price target\" data-tweet=\"$XPO - Citigroup raises its XPO Logistics price target https://seekingalpha.com/news/3320050-citigroup-raises-xpo-logistics-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3320050-citigroup-raises-xpo-logistics-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320049\" data-ts=\"1514303228\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320049-rosenblatt-defends-apple-on-iphone-x-sale-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rosenblatt defends Apple on iPhone X sale cut</a></h4><ul><li>        Rosenblatt <a href=\"https://www.streetinsider.com/Analyst+Comments/Rosenblatt+on+Apple+%28AAPL%29%3A+We+See+No+Evidence+of+Further+Cuts+after+the+Holiday+Season/13630249.html\" target=\"_blank\">defends</a> Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) following this morning&rsquo;s reports of cut iPhone X expectations.</li><li>               Analyst Jun Zhang says the firm&rsquo;s research doesn&rsquo;t indicate any further cuts after the holiday season. Rosenblatt thinks the X has had stable sales in North America, a recent acceleration in China, and has outsold the combined 8 and 8 Plus.&nbsp;</li><li>                  Zhang believes the Taiwanese media reports are &ldquo;referring to previously mentioned iPhone 8/8 Plus production cuts with an iPhone X production ramp in December.&rdquo;    </li><li>               The firm also doesn&rsquo;t see 3D sensing or OLED panel order cuts. &nbsp;&nbsp;</li><li>Apple shares are&nbsp;<font color='red'>down 2.2%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3320010-apple-suppliers-drop-iphone-x-sales-report\" target=\"_blank\">Apple, suppliers drop on iPhone X sales report</a> (Dec. 26)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3320042-stocks-open-lower-techs-weighed-iphone-sales-report\" target=\"_blank\">Stocks open lower as techs weighed by iPhone sales report</a> (Dec. 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3320049\" data-linked=\"Rosenblatt defends Apple on iPhone X sale cut\" data-tweet=\"$AAPL - Rosenblatt defends Apple on iPhone X sale cut https://seekingalpha.com/news/3320049-rosenblatt-defends-apple-on-iphone-x-sale-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3320049-rosenblatt-defends-apple-on-iphone-x-sale-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>54&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320047\" data-ts=\"1514302612\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LJPC\" target=\"_blank\">LJPC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320047-suntrust-raises-la-jolla-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SunTrust raises its La Jolla price target</a></h4><ul>     <li>               SunTrust Robinson Humphrey <a href=\"https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=2&amp;ved=0ahUKEwi6j4zv_qfYAhXCzIMKHSQPDWoQFggtMAE&amp;url=https%3A%2F%2Fwww.streetinsider.com%2FAnalyst%2BComments%2FLa%2BJolla%2BPharma%2B%28LJPC%29%2BPT%2BRaised%2Bto%2B%2465%2Bat%2BSunTrust%2BRobinson%2BHumphrey%3B%2BStreet%2BUnderestimating%2BGiapreza%2BOpportunity%2F13628103.html&amp;usg=AOvVaw07DyG-0B1NnwDyFvkwU5ej\" target=\"_blank\">raises</a> its La Jolla Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/LJPC' title='La Jolla Pharmaceutical Co.'>LJPC</a>) price target from $57 to $65 and maintains a Buy rating.</li>     <li>               Analyst Yatin Suneja cites Giapreza labeling that suggests a potential for broader adoption. &nbsp;&nbsp;</li>     <li>               La Jolla shares are&nbsp;<font color='green'>up 3.8%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3319792-fda-approves-la-jollas-giapreza-blood-pressure-septic-shock-patients\" target=\"_blank\">FDA approves La Jolla's Giapreza for blood pressure in septic shock patients</a> (Dec. 21)</li>      </ul>  &nbsp;<br /><div class=\"tiny-share-widget\" data-id=\"3320047\" data-linked=\"SunTrust raises its La Jolla price target\" data-tweet=\"$LJPC - SunTrust raises its La Jolla price target https://seekingalpha.com/news/3320047-suntrust-raises-la-jolla-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3320047-suntrust-raises-la-jolla-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320040\" data-ts=\"1514299626\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RESN\" target=\"_blank\">RESN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320040-resonant-signs-extended-license-rffe-supplier\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Resonant signs extended license with RFFE supplier</a></h4><ul><li>        Resonant (NASDAQ:<a href='https://seekingalpha.com/symbol/RESN' title='Resonant'>RESN</a>) <a href=\"https://seekingalpha.com/pr/17033977-resonant-expands-licensing-agreement-rffe-supplier-licensee\" target=\"_blank\">announces</a> signing a licensing agreement extension with an existing licensee and RFFEE component supplier.</li><li>               The existing relationship includes licenses for seven duplexers and TDD filters for the Chinese market.&nbsp;</li><li>                  The new agreement adds two high-value duplexers and one WiFi co-existence filter. </li><li>               Resonant shares are&nbsp;<font color='red'>down 1.1%</font>.&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3320040\" data-linked=\"Resonant signs extended license with RFFE supplier\" data-tweet=\"$RESN - Resonant signs extended license with RFFE supplier https://seekingalpha.com/news/3320040-resonant-signs-extended-license-rffe-supplier?source=tweet\" data-url=\"https://seekingalpha.com/news/3320040-resonant-signs-extended-license-rffe-supplier\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320039\" data-ts=\"1514299473\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/M\" target=\"_blank\">M</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320039-retail-names-on-move-on-strong-early-xmas-numbers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Retail names on the move on strong early Xmas numbers</a></h4><ul><li>According to Mastercard, retail sales (ex. autos) <a href=\"https://www.wsj.com/articles/retailers-feel-shoppers-christmas-cheer-1514243102\" target=\"_blank\">rose 4.9% from</a> Nov.1 through Christmas Eve. That's the fastest pace since 2011 and compares to 3.7% for the same period in 2016.</li><li>E-commerce naturally drove the gain, up 18.1%.</li><li>Helping the figure was Christmas falling on a Monday, giving retailers a full weekend to reel in extra sales.</li><li>The Dow and S&amp;P 500 are flat, and the Nasdaq is&nbsp;<font color='red'>lower by 0.5%</font>, but the SPDR Retail SPDR (NYSEARCA:<a href='https://seekingalpha.com/symbol/XRT' title='SPDR S&P Retail ETF'>XRT</a>) is&nbsp;<font color='green'>up more than 1%</font>.</li><li>Macy's (<a href='https://seekingalpha.com/symbol/M' title='Macy&#39;s Inc.'>M</a> <font color='green'>+3.6%</font>), J.C. Penney (<a href='https://seekingalpha.com/symbol/JCP' title='J.C. Penney Company Inc.'>JCP</a> <font color='green'>+4.3%</font>), Kohl's (<a href='https://seekingalpha.com/symbol/KSS' title='Kohl&#39;s Corporation'>KSS</a> <font color='green'>+3.6%</font>), Dillard's (<a href='https://seekingalpha.com/symbol/DDS' title='Dillard&#39;s Inc.'>DDS</a> <font color='green'>+3.5%</font>), Dicks (<a href='https://seekingalpha.com/symbol/DKS' title='Dick&#39;s Sporting Goods, Inc.'>DKS</a> <font color='green'>+2.3%</font>), Target (<a href='https://seekingalpha.com/symbol/TGT' title='Target Corporation'>TGT</a> <font color='green'>+1.2%</font>), Wal-Mart (<a href='https://seekingalpha.com/symbol/WMT' title='Walmart Inc.'>WMT</a> <font color='green'>+0.7%</font>), Foot Locker (<a href='https://seekingalpha.com/symbol/FL' title='Foot Locker, Inc.'>FL</a> <font color='green'>+2.5%</font>), Finish Line (<a href='https://seekingalpha.com/symbol/FINL' title='The Finish Line, Inc.'>FINL</a> <font color='green'>+3%</font>), DSW (<a href='https://seekingalpha.com/symbol/DSW' title='DSW Inc.'>DSW</a> <font color='green'>+3.1%</font>), Abercrombie (<a href='https://seekingalpha.com/symbol/ANF' title='Abercrombie & Fitch'>ANF</a> <font color='green'>+2.9%</font>), Gap (<a href='https://seekingalpha.com/symbol/GPS' title='The Gap, Inc.'>GPS</a> <font color='green'>+1.5%</font>), Express (<a href='https://seekingalpha.com/symbol/EXPR' title='Express, Inc.'>EXPR</a> <font color='green'>+4.6%</font>), Bed Bath &amp; Beyond (<a href='https://seekingalpha.com/symbol/BBBY' title='Bed Bath & Beyond Inc.'>BBBY</a> <font color='green'>+2.1%</font>), Best Buy (<a href='https://seekingalpha.com/symbol/BBY' title='Best Buy Co.'>BBY</a> <font color='green'>+0.7%</font>)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/XLY' title='Consumer Discretionary Select Sector SPDR ETF'>XLY</a>, <a href='https://seekingalpha.com/symbol/XRT' title='SPDR S&P Retail ETF'>XRT</a>, <a href='https://seekingalpha.com/symbol/VCR' title='Vanguard Consumer Discretionary ETF'>VCR</a>, <a href='https://seekingalpha.com/symbol/IBUY' title='Amplify Online Retail ETF'>IBUY</a>, <a href='https://seekingalpha.com/symbol/RTH' title='VanEck Vectors Retail ETF'>RTH</a>, <a href='https://seekingalpha.com/symbol/RETL' title='Direxion Daily Retail Bull 3x Shares ETF'>RETL</a>, <a href='https://seekingalpha.com/symbol/FDIS' title='Fidelity MSCI Consumer Discretionary Index ETF'>FDIS</a>, <a href='https://seekingalpha.com/symbol/IYK' title='iShares U.S. Consumer Goods ETF'>IYK</a>, <a href='https://seekingalpha.com/symbol/FXD' title='First Trust Consumer Discretionary AlphaDEX ETF'>FXD</a>, <a href='https://seekingalpha.com/symbol/EMTY' title='ProShares Decline of the Retail Store ETF'>EMTY</a>, <a href='https://seekingalpha.com/symbol/RCD' title='Invesco S&P Equal Weight Consumer Discretionary ETF'>RCD</a>, <a href='https://seekingalpha.com/symbol/PMR' title='Invesco Dynamic Retail Portfolio ETF'>PMR</a>, <a href='https://seekingalpha.com/symbol/UGE' title='ProShares Ultra Consumer Goods ETF'>UGE</a>, <a href='https://seekingalpha.com/symbol/CLIX' title='ProShares Long Online/Short Stores ETF'>CLIX</a>, <a href='https://seekingalpha.com/symbol/PSCD' title='Invesco S&P SmallCap Consumer Discretionary Portfolio ETF'>PSCD</a>, <a href='https://seekingalpha.com/symbol/SZK' title='ProShares UltraShort Consumer Goods ETF'>SZK</a>, <a href='https://seekingalpha.com/symbol/CNDF' title='iShares Edge MSCI Multifactor Consumer Discretionary ETF'>CNDF</a>, <a href='https://seekingalpha.com/symbol/FTXD' title='First Trust Nasdaq Retail ETF'>FTXD</a>, <a href='https://seekingalpha.com/symbol/JHMC' title='John Hancock Multifactor Consumer Discretionary ETF'>JHMC</a>, <a href='https://seekingalpha.com/symbol/XD' title='Elkhorn S&P MidCap Consumer Discretionary ETF'>XD</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3320039\" data-linked=\"Retail names on the move on strong early Xmas numbers\" data-tweet=\"$M $XRT $M - Retail names on the move on strong early Xmas numbers https://seekingalpha.com/news/3320039-retail-names-on-move-on-strong-early-xmas-numbers?source=tweet\" data-url=\"https://seekingalpha.com/news/3320039-retail-names-on-move-on-strong-early-xmas-numbers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>44&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320037\" data-ts=\"1514298853\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INTC\" target=\"_blank\">INTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320037-intel-loses-semi-lead-for-first-time-in-25-years\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intel loses semi lead for first time in 25 years</a></h4><ul><li>        Intel (NASDAQ:<a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a>) will fall into second place in the semiconductor market for the first time in 25 years, according to <a href=\"https://asia.nikkei.com/Business/Companies/Samsung-to-knock-Intel-off-its-chip-pedestal\" target=\"_blank\">Nikkei Asian Review</a>.</li><li>               Samsung&rsquo;s (<a href='https://seekingalpha.com/symbol/SSNNF' title='Samsung Electronics Co., Ltd.'>OTC:SSNNF</a>, <a href='https://seekingalpha.com/symbol/SSNLF' title='Samsung Electronics Co., Ltd.'>OTC:SSNLF</a>) annual sales earned it top spot this year with $49.2B in revenue from January to September (+46% Y/Y) compared to Intel&rsquo;s $45.7B (+6%).&nbsp;</li><li>               Samsung pushed ahead thanks to exposure to NAND and DRAM and is better positioned to benefit from increasing storage in smartphones and the data center trend.&nbsp;</li><li>               Intel relies on CPUs sold to PC makers and the PC market has slowed in the year.&nbsp;</li><li>               Intel shares are&nbsp;<font color='red'>down 1.1%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3319959-venture-capital-deals-week\" target=\"_blank\">Venture capital deals of the week</a> (Dec. 23)</li></ul><div class=\"tiny-share-widget\" data-id=\"3320037\" data-linked=\"Intel loses semi lead for first time in 25 years\" data-tweet=\"$INTC $INTC $SSNNF - Intel loses semi lead for first time in 25 years https://seekingalpha.com/news/3320037-intel-loses-semi-lead-for-first-time-in-25-years?source=tweet\" data-url=\"https://seekingalpha.com/news/3320037-intel-loses-semi-lead-for-first-time-in-25-years\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320034\" data-ts=\"1514298236\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IGC\" target=\"_blank\">IGC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320034-india-globalizationplus-122-on-blockchain-announcement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">India Globalization +122% on blockchain announcement</a></h4><ul>     <li>India Globalization Capital (<a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc'>OTC:IGC</a>) <font color='green'>+122.4%</font> premarket after saying it will begin using blockchain in areas such as product identification assurance.</li>     <li>IGC, which is working on a cannabis treatment for Alzheimer's disease, cites a recent study that says nearly 70% of all cannabidiol products sold online are either over or under labeled.</li>     <li>\"As we work to develop blockchain in the rollout of Hyalolex, our goal would be to establish a universal cannabis platform applicable to solving multiple industry challenges facing dispensaries and consumers,\"&nbsp;IGC says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3320034\" data-linked=\"India Globalization +122% on blockchain announcement\" data-tweet=\"$IGC - India Globalization +122% on blockchain announcement https://seekingalpha.com/news/3320034-india-globalizationplus-122-on-blockchain-announcement?source=tweet\" data-url=\"https://seekingalpha.com/news/3320034-india-globalizationplus-122-on-blockchain-announcement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320033\" data-ts=\"1514297973\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320033-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/APTO' title='Aptose Biosciences Inc.'>APTO</a>&nbsp;<font color='green'>+22%</font>&nbsp;after FDA grants <a href=\"https://seekingalpha.com/news/3320015-fda-grants-orphan-drug-designation-aptoses-cg-806-aml-shares-ahead-32-percent-premarket\" target=\"_blank\">Orphan Drug designation</a> to CG&rsquo;806 in AML.</li><li><a href='https://seekingalpha.com/symbol/FTFT' title='Future Fintech Group Inc'>FTFT</a> <font color='green'>+15%</font>.</li><li><a href='https://seekingalpha.com/symbol/LFIN' title='LongFin Corp.A'>OTCPK:LFIN</a>&nbsp;<font color='green'>+14%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3319998-bitcoin-cryptos-back-recovery-mode\" target=\"_blank\">Bitcoin</a> rally.</li><li><a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>&nbsp;<font color='green'>+12%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/news/3319998-bitcoin-cryptos-back-recovery-mode\" target=\"_blank\">Bitcoin</a>&nbsp;rally.</li><li><a href='https://seekingalpha.com/symbol/ONVO' title='Organovo Holdings, Inc.'>ONVO</a>&nbsp;<font color='green'>+12%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3320031-organovo-receives-odd-treatment-alphaminus-1-antitrypsin-deficiency\" target=\"_blank\">receiving</a>&nbsp;ODD for the treatment of Alpha-1 Antitrypsin deficiency.</li><li><a href='https://seekingalpha.com/symbol/NETE' title='Net Element International, Inc.'>NETE</a> <font color='green'>+11%</font>.</li><li><a href='https://seekingalpha.com/symbol/IPWR' title='Ideal Power Inc.'>IPWR</a> <font color='green'>+11%</font>.</li><li><a href='https://seekingalpha.com/symbol/OTIV' title='On Track Innovations Ltd'>OTIV</a> <font color='green'>+11%</font>.</li><li><a href='https://seekingalpha.com/symbol/INSY' title='Insys Therapeutics, Inc.'>INSY</a>&nbsp;<font color='green'>+9%</font>&nbsp;on FDA <a href=\"https://seekingalpha.com/news/3320027-fda-grants-insys-therapeutics-fast-track-designation-cannabidiol-oral-solution-treatment\" target=\"_blank\">granting</a>&nbsp;Fast Track designation for Cannabidiol oral solution for the treatment for Prader-Willi syndrome.</li><li><a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a> <font color='green'>+8%</font>.</li><li><a href='https://seekingalpha.com/symbol/NXTD' title='NXT-ID Inc.'>NXTD</a> <font color='green'>+7%</font>.</li><li><a href='https://seekingalpha.com/symbol/GROW' title='U.S. Global Investors, Inc.'>GROW</a>&nbsp;<font color='green'>+7%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/news/3319998-bitcoin-cryptos-back-recovery-mode\" target=\"_blank\">Bitcoin</a>&nbsp;rally.</li><li><a href='https://seekingalpha.com/symbol/MARA' title='Marathon Patent Group, Inc.'>MARA</a>&nbsp;<font color='green'>+7%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/news/3319998-bitcoin-cryptos-back-recovery-mode\" target=\"_blank\">Bitcoin</a>&nbsp;rally.</li><li><a href='https://seekingalpha.com/symbol/NHLD' title='National Holdings Corp.'>NHLD</a> <font color='green'>+7%</font>.</li><li><a href='https://seekingalpha.com/symbol/SSC-OLD' title='Seven Stars Cloud Group, Inc.'>SSC-OLD</a>&nbsp;<font color='green'>+6%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/news/3319998-bitcoin-cryptos-back-recovery-mode\" target=\"_blank\">Bitcoin</a>&nbsp;rally.</li><li><a href='https://seekingalpha.com/symbol/SIEB' title='Siebert Financial Corp.'>SIEB</a> <font color='green'>+6%</font>.</li><li><a href='https://seekingalpha.com/symbol/SCMP' title='Sucampo Pharmaceuticals, Inc.'>SCMP</a>&nbsp;<font color='green'>+5%</font>&nbsp;after Mallinckrodt (NYSE:<a href='https://seekingalpha.com/symbol/MNK' title='Mallinckrodt PLC'>MNK</a>) <a href=\"https://seekingalpha.com/news/3320008-mallinckrodt-seals-deal-sucampo-pharma\" target=\"_blank\">agreed</a> to pay $18 per share in cash for&nbsp;a total deal value of $1.2B.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3320033\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$APTO $FTFT $LFIN - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3320033-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3320033-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320031\" data-ts=\"1514297173\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ONVO\" target=\"_blank\">ONVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320031-organovo-receives-odd-for-treatment-of-alphaminus-1-antitrypsin-deficiency\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Organovo receives ODD for the treatment of Alpha-1 Antitrypsin deficiency</a></h4><ul> <li>Organovo Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/ONVO' title='Organovo Holdings, Inc.'>ONVO</a>) <a href=\"https://seekingalpha.com/pr/17033972-organovo-receives-orphan-designation-u-s-fda-3d-bioprinted-therapeutic-liver-tissue-treatment\" target=\"_blank\">announces</a> that the FDA has granted orphan drug designation for the Company&rsquo;s treatment of <a href=\"https://en.wikipedia.org/wiki/Alpha_1-antitrypsin_deficiency\" target=\"_blank\">alpha-1 antitrypsin deficiency</a> (&ldquo;A1AT&rdquo;) with its 3D bioprinted liver therapeutic tissue.</li><li>Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.</li>     <li>A1AT is a rare inherited disorder that severely damages the lungs and liver.</li><li>Shares are up&nbsp;<font color='green'>10%</font>&nbsp;premarket on robust volume.</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3320031\" data-linked=\"Organovo receives ODD for the treatment of Alpha-1 Antitrypsin deficiency\" data-tweet=\"$ONVO - Organovo receives ODD for the treatment of Alpha-1 Antitrypsin deficiency https://seekingalpha.com/news/3320031-organovo-receives-odd-for-treatment-of-alphaminus-1-antitrypsin-deficiency?source=tweet\" data-url=\"https://seekingalpha.com/news/3320031-organovo-receives-odd-for-treatment-of-alphaminus-1-antitrypsin-deficiency\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320030\" data-ts=\"1514297091\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KED\" target=\"_blank\">KED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320030-kayne-anderson-says-tax-bill-boosts-net-asset-value\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kayne Anderson says tax bill boosts net asset value</a></h4><ul>     <li>Kayne Anderson Energy (NYSE:<a href='https://seekingalpha.com/symbol/KED' title='Kayne Anderson Energy Development'>KED</a>) <font color='green'>+4%</font> premarket after saying the new tax cut legislation would <a href=\"https://seekingalpha.com/pr/17033818-kayne-anderson-energy-development-company-announces-impact-tax-reform-net-asset-value\" target=\"_blank\">positively affect</a> the company&rsquo;s net asset value.</li>     <li>KED says its net asset value per share was  $17.87 as of Dec. 22, which included an increase of $0.98, or 5.8%, as a result of the enactment of the tax reform bill.</li>     <li>KED says the bill, which allows for a 21% federal corporate tax rate, will significantly reduce its deferred tax liability and result in a higher net asset value going forward.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3320030\" data-linked=\"Kayne Anderson says tax bill boosts net asset value\" data-tweet=\"$KED - Kayne Anderson says tax bill boosts net asset value https://seekingalpha.com/news/3320030-kayne-anderson-says-tax-bill-boosts-net-asset-value?source=tweet\" data-url=\"https://seekingalpha.com/news/3320030-kayne-anderson-says-tax-bill-boosts-net-asset-value\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320027\" data-ts=\"1514296258\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INSY\" target=\"_blank\">INSY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320027-fda-grants-insys-therapeutics-fast-track-designation-for-cannabidiol-oral-solution-for\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA grants INSYS Therapeutics Fast Track designation for Cannabidiol oral solution for the treatment for Prader-Willi syndrome</a></h4><ul> <li>INSYS Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/INSY' title='Insys Therapeutics, Inc.'>INSY</a>) <a href=\"https://seekingalpha.com/pr/17033981-fda-grants-insys-therapeutics-fast-track-designation-cannabidiol-cbd-oral-solution\" target=\"_blank\">announces</a> that the FDA has granted Fast Track designation to the company&rsquo;s <a href=\"https://www.insysrx.com/products/in-development\" target=\"_blank\">cannabidiol</a> &#40;CBD&#41; oral solution for the treatment of <a href=\"https://ghr.nlm.nih.gov/condition/prader-willi-syndrome\" target=\"_blank\">Prader-Willi syndrome</a>.</li><li>Fast Track status provides for more frequent interactions with the FDA review team and a rolling review of the marketing application.</li><li>Prader-Willi syndrome&nbsp;is an inherited disorder characterized by weak muscle tone, feeding difficulties, delayed development and poor growth. Affected people develop an insatiable appetite that leads to obesity.</li><li>Shares are up&nbsp;<font color='green'>11%</font>&nbsp;premarket on light volume.</li>             </ul><div class=\"tiny-share-widget\" data-id=\"3320027\" data-linked=\"FDA grants INSYS Therapeutics Fast Track designation for Cannabidiol oral solution for the treatment for Prader-Willi syndrome\" data-tweet=\"$INSY $INSYQ - FDA grants INSYS Therapeutics Fast Track designation for Cannabidiol oral solution for the treatment for Prader-Willi syndrome https://seekingalpha.com/news/3320027-fda-grants-insys-therapeutics-fast-track-designation-for-cannabidiol-oral-solution-for?source=tweet\" data-url=\"https://seekingalpha.com/news/3320027-fda-grants-insys-therapeutics-fast-track-designation-for-cannabidiol-oral-solution-for\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320026\" data-ts=\"1514296230\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTLA\" target=\"_blank\">PTLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320026-portola-pharmaminus-6-on-delay-in-fda-review-of-andexxa\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Portola Pharma -6% on delay in FDA review of AndexXa</a></h4><ul>     <li>Portola Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PTLA' title='Portola Pharmaceuticals'>PTLA</a>) <font color='red'>-5.8%</font> premarket following news after Friday's close that the <a href=\"https://seekingalpha.com/pr/17033798-portola-pharmaceuticals-provides-update-biologics-license-application-bla-andexxa-andexanet\" target=\"_blank\">FDA will extend its review</a> of its AndexXa biologic drug by 90 days to May 4, 2018.</li>     <li>The company says it has submitted additional data requested by the FDA for the ongoing ANNEXA-4 study as part of the continuing review process.</li>     <li>PTLA is seeking initial approval of AndexXa for reversal of the anticoagulant effects of apixaban and rivaroxaban in patients experiencing uncontrolled or life-threatening bleeding.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3320026\" data-linked=\"Portola Pharma -6% on delay in FDA review of AndexXa\" data-tweet=\"$PTLA - Portola Pharma -6% on delay in FDA review of AndexXa https://seekingalpha.com/news/3320026-portola-pharmaminus-6-on-delay-in-fda-review-of-andexxa?source=tweet\" data-url=\"https://seekingalpha.com/news/3320026-portola-pharmaminus-6-on-delay-in-fda-review-of-andexxa\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320021\" data-ts=\"1514294616\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320021-raymond-james-watch-amazons-otc-drug-line\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Raymond James: Watch Amazon&#39;s OTC drug line</a></h4><ul><li>A Raymond James analyst says Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) investors should pay attention to a new line of over-the-counter medications called &ldquo;Basic Care.&rdquo;</li><li>Analyst John W. Ransom notes that the line is Amazon&rsquo;s &ldquo;first baby step into a more complete competitive threat to the drug retailers.&rdquo;</li><li>The Basic Care products often have a lower price point than similar products sold at drugstores. Basic Care is a trademark of Perrigo (NASDAQ:<a href='https://seekingalpha.com/symbol/PRGO' title='Perrigo Company'>PRGO</a>), which has sold drugs on Amazon under the Good Sense brand for years.</li><li>Source: Bloomberg First Word</li><li>Amazon shares are&nbsp;<font color='red'>down 0.3%</font>&nbsp;premarket.</li><li>Health stocks that could move on the news include CVS Health (NYSE:<a href='https://seekingalpha.com/symbol/CVS' title='CVS Health Corporation'>CVS</a>) and Walgreens Boots Alliance (NASDAQ:<a href='https://seekingalpha.com/symbol/WBA' title='Walgreens Boots Alliance, Inc.'>WBA</a>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3320021\" data-linked=\"Raymond James: Watch Amazon&#39;s OTC drug line\" data-tweet=\"$AMZN $AMZN $PRGO - Raymond James: Watch Amazon&#39;s OTC drug line https://seekingalpha.com/news/3320021-raymond-james-watch-amazons-otc-drug-line?source=tweet\" data-url=\"https://seekingalpha.com/news/3320021-raymond-james-watch-amazons-otc-drug-line\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320015\" data-ts=\"1514292979\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APTO\" target=\"_blank\">APTO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320015-fda-grants-orphan-drug-designation-to-aptoses-cg-806-in-aml-shares-ahead-32-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA grants Orphan Drug designation to Aptose&#39;s CG\u2019806 in AML; shares ahead 32% premarket</a></h4><ul> <li>Aptose Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/APTO' title='Aptose Biosciences Inc.'>APTO</a>) <a href=\"https://seekingalpha.com/pr/17033942-fda-grants-orphan-drug-designation-aptose-biosciences-cg-806-acute-myeloid-leukemia\" target=\"_blank\">announces</a> that the FDA has granted orphan drug designation to <a href=\"http://aptose.com/cg806/\" target=\"_blank\">CG&rsquo;806</a>, a highly potent pan-FLT3/pan-BTK inhibitor, for the treatment of patients with acute myeloid leukemia &#40;AML&#41;.</li>   <li>Among the benefits of the Orphan Drug designation is a seven-year period of market exclusivity if approved.</li><li>AML is a particularly devastating cancer of the blood and bone marrow and is the most common type of acute leukemia among adults.</li><li>Shares are up&nbsp;<font color='green'>32%</font>&nbsp;premarket on increased volume.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3320015\" data-linked=\"FDA grants Orphan Drug designation to Aptose&#39;s CG\u2019806 in AML; shares ahead 32% premarket\" data-tweet=\"$APTO - FDA grants Orphan Drug designation to Aptose&#39;s CG\u2019806 in AML; shares ahead 32% premarket https://seekingalpha.com/news/3320015-fda-grants-orphan-drug-designation-to-aptoses-cg-806-in-aml-shares-ahead-32-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3320015-fda-grants-orphan-drug-designation-to-aptoses-cg-806-in-aml-shares-ahead-32-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320010\" data-ts=\"1514291034\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320010-apple-suppliers-drop-on-iphone-x-sales-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple, suppliers drop on iPhone X sales report</a></h4><ul><li>        Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) will cut its Q1 <a href=\"https://in.reuters.com/article/us-apple-iphone/apple-suppliers-drop-on-report-of-weak-iphone-x-demand-analysts-views-mixed-idINKBN1EK0MH\" target=\"_blank\">sales forecast</a> for the iPhone X from 50M units to 30M units, according to Taiwan&rsquo;s Economic Daily.</li><li>               Analyst estimates: JL Warren Capital predicts 5M due to &ldquo;high price point and a lack of interesting innovations.&rdquo; Loop Capital predicts 40M to 45M units in Q1and Jefferies expects 40M units.&nbsp;</li><li>               Apple suppliers moving on the report: Skyworks (NASDAQ:<a href='https://seekingalpha.com/symbol/SWKS' title='Skyworks Solutions, Inc.'>SWKS</a>) shares are&nbsp;<font color='red'>down 2.2%</font>&nbsp;premarket, Cirrus Logic (NASDAQ:<a href='https://seekingalpha.com/symbol/CRUS' title='Cirrus Logic, Inc.'>CRUS</a>) shares are&nbsp;<font color='red'>down 2.4%</font>, and Qorvo (NASDAQ:<a href='https://seekingalpha.com/symbol/QRVO' title='Qorvo, Inc'>QRVO</a>) shares are&nbsp;<font color='red'>down 1.8%</font>.&nbsp;</li><li>               Apple shares are&nbsp;<font color='red'>down 2.3%</font>. &nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3317276-digitimes-apple-suppliers-shipments-month-expect-weak-dec\" target=\"_blank\">Digitimes: Apple suppliers shipments down on month, expect weak Dec.</a> (Dec. 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3320010\" data-linked=\"Apple, suppliers drop on iPhone X sales report\" data-tweet=\"$AAPL $AAPL $SWKS - Apple, suppliers drop on iPhone X sales report https://seekingalpha.com/news/3320010-apple-suppliers-drop-on-iphone-x-sales-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3320010-apple-suppliers-drop-on-iphone-x-sales-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>166&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320008\" data-ts=\"1514290254\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNK\" target=\"_blank\">MNK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320008-mallinckrodt-seals-deal-for-sucampo-pharma\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mallinckrodt seals deal for Sucampo Pharma</a></h4><ul><li>Mallinckrodt (NYSE:<a href='https://seekingalpha.com/symbol/MNK' title='Mallinckrodt PLC'>MNK</a>) has agreed to pay $18 per share in cash for Sucampo (NASDAQ:<a href='https://seekingalpha.com/symbol/SCMP' title='Sucampo Pharmaceuticals, Inc.'>SCMP</a>), for a total deal value of $1.2B.</li><li>MNK expects EPS accretion of at least $0.30 in 2018, and at least double that amount in 2019, assuming a close in Q1 of 2018.</li><li>SCMP&nbsp;<font color='green'>+4.7%</font>&nbsp;to $17.80 premarket</li><li>Previously: <a href=\"https://seekingalpha.com/news/3317040-sucampo-mulling-acquisition-offer-shares-5-percent\" target=\"_blank\">Sucampo mulling acquisition offer; shares up 5%</a> (Dec. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3320008\" data-linked=\"Mallinckrodt seals deal for Sucampo Pharma\" data-tweet=\"$MNK $MNK $SCMP - Mallinckrodt seals deal for Sucampo Pharma https://seekingalpha.com/news/3320008-mallinckrodt-seals-deal-for-sucampo-pharma?source=tweet\" data-url=\"https://seekingalpha.com/news/3320008-mallinckrodt-seals-deal-for-sucampo-pharma\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3320004\" data-ts=\"1514288430\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DMPI\" target=\"_blank\">DMPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3320004-delmar-pharmaceuticals-announces-fast-track-designation-for-valminus-083-in-recurrent\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DelMar Pharmaceuticals announces Fast Track designation for VAL-083 in recurrent Glioblastoma</a></h4><ul><li>DelMar Pharmaceuticals&nbsp;(NASDAQ:<a href='https://seekingalpha.com/symbol/DMPI' title='DelMar Pharmaceuticals, Inc.'>DMPI</a>) <a href=\"https://seekingalpha.com/pr/17033900-delmar-pharmaceuticals-announces-fast-track-designation-valminus-083-recurrent-glioblastoma\" target=\"_blank\">announces</a> that the FDA has granted Fast Track designation for VAL-083, in recurrent <a href=\"https://en.wikipedia.org/wiki/Glioblastoma\" target=\"_blank\">glioblastoma</a> (rGBM).</li>  <li>This Fast Track status applies to two ongoing clinical trials:</li><li>A <a href=\"https://seekingalpha.com/pr/17008965-delmar-presents-positive-interim-results-valminus-083-study-mgmt-unmethylated-recurrent-gbm\" target=\"_blank\">Phase 2 study in bevacizumab-na&iuml;ve MGMT-unmethylated GBM patients</a>; and</li><li>A Phase 3 study of patients whose disease has progressed following prior treatment with temozolomide and bevacizumab (the STAR-3 trial).</li><li>Fast Track status provides for more frequent interactions with the FDA review team and a rolling review of the marketing application.</li><li>VAL-083 (dianhydrogalactitol), an orphan drug designation is a DNA-targeting agent that introduces interstrand DNA cross-links at the N7-position of guanine leading to DNA double-strand breaks and cancer cell death.</li><li>Shares are up&nbsp;<font color='green'>20%</font>&nbsp;premarket on modest volume.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3320004\" data-linked=\"DelMar Pharmaceuticals announces Fast Track designation for VAL-083 in recurrent Glioblastoma\" data-tweet=\"$DMPI - DelMar Pharmaceuticals announces Fast Track designation for VAL-083 in recurrent Glioblastoma https://seekingalpha.com/news/3320004-delmar-pharmaceuticals-announces-fast-track-designation-for-valminus-083-in-recurrent?source=tweet\" data-url=\"https://seekingalpha.com/news/3320004-delmar-pharmaceuticals-announces-fast-track-designation-for-valminus-083-in-recurrent\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":34,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}